EricPadronMD

PubMed

• RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis.
  Nana Adjoa Ben-Crentsil, Wazim Mohammed Ismail, Maria E Balasis, Hannah Newman, Ariel Quintana
  Cancer Discovery. 2024-12-02
• Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
  Douglas Tremblay, Clifford Csizmar, Courtney D DiNardo, Somedeb Ball, Noa Rippel
  Leukemia. 2024-11-12
• 5 citations
  Risk prediction for clonal cytopenia: multicenter real-world evidence.
  Zhuoer Xie, Rami Komrokji, Najla Al Ali, Alexandra Regelson, Susan Geyer
  Blood. 2024-11-07

Journal Articles

• Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative Neoplasm  
  Erik A Ranheim, David Yang, Warren S Pear, Lan Zhou, Mignon Loh, Eric Padron, Elliot Stieglitz, Nature

Abstracts/Posters

• SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti_Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocyti...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Gr...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All-Trans retinoic Acid (ATRA) through the T...
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
  Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all